Piedmont Investment Advisors Inc. acquired a new position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 6,449 shares of the company’s stock, valued at approximately $793,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Steward Partners Investment Advisory LLC acquired a new stake in shares of Neurocrine Biosciences during the 3rd quarter worth $127,000. TRUE Private Wealth Advisors purchased a new stake in Neurocrine Biosciences during the 3rd quarter worth $127,000. Meeder Asset Management Inc. boosted its position in Neurocrine Biosciences by 643.7% during the 2nd quarter. Meeder Asset Management Inc. now owns 1,123 shares of the company’s stock worth $110,000 after purchasing an additional 972 shares during the period. Financial Architects Inc boosted its position in Neurocrine Biosciences by 283.7% during the 3rd quarter. Financial Architects Inc now owns 1,385 shares of the company’s stock worth $170,000 after purchasing an additional 1,024 shares during the period. Finally, Hartford Investment Management Co. purchased a new stake in Neurocrine Biosciences during the 3rd quarter worth $207,000. Institutional investors and hedge funds own 98.88% of the company’s stock.

Shares of NBIX stock opened at $88.49 on Wednesday. Neurocrine Biosciences, Inc. has a one year low of $67.32 and a one year high of $126.98. The stock has a market cap of $7.92 billion, a PE ratio of -54.62, a P/E/G ratio of 22.34 and a beta of 0.94.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings results on Monday, November 5th. The company reported $0.52 EPS for the quarter, topping the consensus estimate of $0.48 by $0.04. Neurocrine Biosciences had a net margin of 2.40% and a return on equity of 2.54%. The business had revenue of $151.80 million for the quarter, compared to analysts’ expectations of $151.51 million. During the same quarter last year, the company posted ($0.13) earnings per share. The company’s quarterly revenue was up 149.7% compared to the same quarter last year. On average, research analysts forecast that Neurocrine Biosciences, Inc. will post 0.19 EPS for the current fiscal year.

In other news, Director Gary A. Lyons sold 15,000 shares of the stock in a transaction dated Friday, November 2nd. The shares were sold at an average price of $114.41, for a total transaction of $1,716,150.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Richard F. Pops sold 5,500 shares of the stock in a transaction dated Monday, October 29th. The stock was sold at an average price of $107.13, for a total transaction of $589,215.00. Following the transaction, the director now directly owns 37,759 shares in the company, valued at approximately $4,045,121.67. The disclosure for this sale can be found here. Insiders have sold 33,623 shares of company stock worth $3,721,361 in the last ninety days. Corporate insiders own 4.30% of the company’s stock.

A number of analysts recently weighed in on the stock. ICAP decreased their price target on shares of Neurocrine Biosciences from $140.00 to $128.00 and set an “outperform” rating for the company in a research report on Tuesday, September 4th. Oppenheimer set a $140.00 price objective on shares of Neurocrine Biosciences and gave the company a “buy” rating in a research report on Tuesday, September 4th. Cantor Fitzgerald assumed coverage on shares of Neurocrine Biosciences in a research report on Friday, September 14th. They issued a “buy” rating and a $150.00 price objective for the company. Stifel Nicolaus upped their price objective on shares of Neurocrine Biosciences from $137.00 to $142.00 and gave the company a “buy” rating in a research report on Thursday, September 20th. Finally, BidaskClub cut shares of Neurocrine Biosciences from a “buy” rating to a “hold” rating in a research report on Saturday, September 15th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and seventeen have given a buy rating to the company. Neurocrine Biosciences presently has a consensus rating of “Buy” and a consensus target price of $124.88.

TRADEMARK VIOLATION WARNING: This report was originally published by Daily Political and is owned by of Daily Political. If you are reading this report on another site, it was illegally stolen and republished in violation of United States and international copyright laws. The original version of this report can be read at https://www.dailypolitical.com/2018/11/21/piedmont-investment-advisors-inc-invests-793000-in-neurocrine-biosciences-inc-nbix.html.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trial for use in women's health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trial that is used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease.

Featured Article: Discover Your Risk Tolerance

Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurocrine Biosciences, Inc. (NASDAQ:NBIX).

Institutional Ownership by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.